

**Date: 14 May 2025**

To <b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife	To <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
---	--

**Sub: Press release for the Financial Results for the quarter and year ending 31<sup>st</sup> March 2025**

Dear Sir/ Madam,

With reference to the above subject, we enclose herewith the Press release for the Financial results for the quarter and year ended 31 March 2025.

We request you to take note of the same and oblige.

Thank you.

For **Sai Life Sciences Limited**

---

**Runa Karan**  
**Company Secretary & Compliance Officer**  
**Membership No.: A13721**

**Encl: As above**

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey  
#133, Gachibowli Miyapur Road,  
Gachibowli, Hyderabad – 500032,  
Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally  
(V), Shameerpet Mandal, Medchal-Malkajgiri  
(Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: [info@sailife.com](mailto:info@sailife.com)  
W: [www.sailife.com](http://www.sailife.com)

## Sai Life Sciences Limited reports robust FY25 results

Revenue grows by 16%; Net Profit up 105% year-on-year

**Hyderabad, May 14, 2025:** Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO) announced its financial results for the fourth quarter and full year ended March 31, 2025.

### Financial Performance:

Particulars (₹ crores)	FY25	FY24	YoY%	Q4FY25	Q4FY24	YoY%
Revenue from Operations	1695	1,465	16%	580	439	32%
EBITDA	425	300	42%	161	124	30%
EBITDA Margin%	25%	20%	-	28%	28%	-
PBT	228	109	108%	119	76	56%
PAT	170	83	105%	88	56	57%
PAT Margin%	10%	6%	-	15%	13%	-

### FY25 Highlights

- Revenue from Operations was ₹1695 Cr for FY25 compared to ₹1,465 Cr in FY24, **an increase of 16%**
- EBITDA stood at ₹425 Cr. for FY25 compared to ₹300 Cr in FY24. **an increase of 42%**
- PAT stood at ₹170Cr. for FY25 compared to ₹83 Cr in FY24, **an increase of 105%**

### Q4FY25 Highlights

- Revenue from Operations was ₹580 Cr for Q4FY25 compared to ₹439 Cr in Q4FY24, **an increase of 32%**
- EBITDA stood at ₹161 Cr. for Q4FY25 compared to ₹124 Cr. in Q4FY24, **an increase of 30%**
- PAT stood at ₹88 Cr. for Q4FY25 compared to ₹56 Cr. in Q4FY24, **an increase of 57%**

**Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said,** “We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners.

One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics.

With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients.

As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.”

**Mr. Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences Limited added,** “We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned ₹720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26.

Capex for the year stood at ₹ 408Cr, focused on enhancing our manufacturing footprint and expanding discovery capabilities.

*We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.”*

### Earnings Call:

Sai Life Sciences will conduct earnings call at 4.00 PM (IST) on 14 May 2025 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

<b>Date</b>	<b>May 14, 2025</b>
<b>Time</b>	04:00 PM – 5:00 PM (IST)
<b>Dial-in Number</b>	<b>+91 22 6280 1107, +91 22 7115 8008</b>
<b>International Toll Free</b>	USA: 18667462133   UK: 08081011573   Singapore: 8001012045   Hong Kong: 800964448
<b>Pre-Registration Facility</b>	<a href="#">Click Here</a>

### About Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE)

Sai Life Sciences is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit [www.sailife.com](http://www.sailife.com)

For further details, please feel free to contact: [Investorrelation@sailife.com](mailto:Investorrelation@sailife.com)

### Disclaimer:

*This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.*